Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020657 · ClinicalTrials.gov registry record · Phase 3
Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer
A Phase 3 study, sponsored by Gary Morrow.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00020657 is a Phase 3 study that has completed, run by Gary Morrow.
The verdict
NCT00020657, a Phase 3 study, has completed, sponsored by Gary Morrow.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer.
Interventions
- PROCEDURE quality-of-life assessment
- DRUG ondansetron
- DRUG dolasetron mesylate
- DRUG granisetron hydrochloride
- DRUG prochlorperazine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020657
The ClinicalTrials.gov registry entry for NCT00020657 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gary Morrow, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which quality-of-life assessment is the first listed.
NCT00020657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020657 about?
NCT00020657 is a clinical study titled "Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer". RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer.
What is the current status of trial NCT00020657?
This trial is currently completed. It is a Phase 3 study. The study started on 2001-07. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00020657?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), ondansetron (DRUG), dolasetron mesylate (DRUG), granisetron hydrochloride (DRUG), prochlorperazine (DRUG).
Who is sponsoring clinical trial NCT00020657?
This trial is sponsored by Gary Morrow, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.